Meridian Reports 1 Percent Drop in Q1 Revenues; Mixed Results in Dx, Life Science Segments | GenomeWeb

NEW YORK (GenomeWeb News) — Meridian Bioscience today reported a 1 percent year-over-year drop in fiscal 2014 first-quarter revenues with mixed results in both its Illumigene molecular diagnostics and core life science businesses.

For the three months ended Dec. 31, Meridian reported revenues of $44.8 million, compared to $45.4 million in the year-ago period and well short of the consensus analyst estimate of $49 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.